Evidence map›Paper›PMID 39819357›Full record

ArticleJournal of cheminformatics2025

One size does not fit all: revising traditional paradigms for assessing accuracy of QSAR models used for virtual screening.

James Wellnitz, Sankalp Jain, Joshua E Hochuli, Travis Maxfield, Eugene N Muratov, Alexander Tropsha, Alexey V Zakharov

Abstract readLetter
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Continuous Inhibition-Zone Modeling and Binary Classification forPharmaceuticals (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

James WellnitzDivision of Chemical Biology and Medicinal Chemistry, Laboratory for Molecular Modeling,, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.
Sankalp JainNational Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 9800 Medical Center Drive, Rockville, MD, 20850, USA.
Joshua E HochuliDivision of Chemical Biology and Medicinal Chemistry, Laboratory for Molecular Modeling,, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.
Travis MaxfieldDivision of Chemical Biology and Medicinal Chemistry, Laboratory for Molecular Modeling,, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.
Eugene N MuratovDivision of Chemical Biology and Medicinal Chemistry, Laboratory for Molecular Modeling,, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA. murik@email.unc.edu.
Alexander TropshaDivision of Chemical Biology and Medicinal Chemistry, Laboratory for Molecular Modeling,, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA. tropsha@email.unc.edu.
Alexey V ZakharovNational Center for Advancing Translational Sciences (NCATS), National Institutes of Health, 9800 Medical Center Drive, Rockville, MD, 20850, USA. alexey.zakharov@nih.gov.

Funding

Enabling the Accelerated Discovery of Novel Chemical Probes by Integration of Crystallographic, Computational, and Synthetic Chemistry ApproachesR01GM140154 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TROPSHA, ALEXANDER, WILLSON, TIMOTHY M · 2021 to 2024
$2.4M
UNC Chemical Biology Interface Training ProgramT32GM135122 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jeffrey Aube · 2021 to 2026
$1.6M
GEM BIOMEDICAL/BIOENGINEERING RESEARCH INITIATIVET36GM008633 · NIGMS · GEM CONSORTIUM · PI JOHNSON, SAUNDRA D · 1996 to 1996
–
NIGMS NIH HHS R01 GM140154NIGMS NIH HHS T32GM08633NIGMS NIH HHS T32GM135122NIGMS NIH HHS T36 GM008633NIH HHS R01GM140154NSF DMS2344256
6 · The paper itself

Abstract

Traditional best practices for quantitative structure activity relationship (QSAR) modeling recommend dataset balancing and balanced accuracy (BA) as the key desired objective of model development. This study explores the value of the conventional norms in the context of using QSAR models for virtual screening of modern large and ultra-large chemical libraries. For this increasingly common task, we now recommend the use of models with the highest positive predictive value (PPV) built on imbalanced training sets as preferred virtual screening tools. This recommendation stems from practical considerations of how the results of virtual screening are used in experimental laboratories where only a small fraction of virtually screened molecules can be tested using standard well plates. As a proof of concept, we have developed QSAR models for five expansive datasets with different ratios of active and inactive molecules and compared model performance in virtual screening using BA, PPV, and other metrics. We show that training on imbalanced datasets achieves a hit rate at least 30% higher than using balanced datasets, and that the PPV metric captured this difference of performance with no parameter tuning. Importantly, hit rates were estimated for top scoring compounds organized in batches of the size of plates (for instance, 128 molecules) used in the experimental high throughput screening. Based on the results of our studies, we posit that QSAR models trained on imbalanced datasets with the highest PPV should be relied upon to identify and test hit compounds in early drug discovery studies.

Indexed as

Computer-assisted drug discoveryHit rateImbalanced datasetsPositive predictive valueQSAR modelingVirtual screening

Identifiers

PMID39819357
PMCPMC11740363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.